论文部分内容阅读
本文对４组共３００人的血清磷酸葡萄糖异构酶（ＧＰＩ）活性和癌胚抗原（ＣＥＡ）同时进行了测定，结果肺癌组、其它恶性肿瘤组患者的血清ＧＰＩ活性显著高于健康对照组和肺良性疾病组。肺癌组的阳性率为６６．７％，其它恶性肿瘤组的阳性率为４９．５％；肺癌中以小细胞癌和腺鳞癌的阳性率为高，达８０％以上，消化系肿瘤中以肝胆胰恶性肿瘤的阳性率较高，达７８％以上。ＧＰＩ活性的敏感度高于ＣＥＡ，而ＣＥＡ的特异性高于ＧＰＩ，两者联合应用，可提高肺癌患者的诊断效率和正确诊断率。文章对ＧＰＩ活性作为肺癌标记物的地位和临床应用价值进行了讨论，认为血清ＧＰＩ活性的测定方法简便，可靠和价廉，值得今后在临床上推广应用
In this paper, serum GLP activity and CEA of four groups of 300 individuals were measured simultaneously. The results showed that serum GPI activity in patients with lung cancer and other malignant tumors was significantly higher than that in healthy controls. Lung benign disease group. The positive rate of lung cancer group was 66.7%, and the positive rate of other malignant tumors was 49.5%. The positive rate of small cell carcinoma and adenosquamous carcinoma in lung cancer was high, reaching over 80%. The positive rate of hepatobiliary and pancreatic malignancies was high, reaching over 78%. The sensitivity of GPI activity is higher than that of CEA, but the specificity of CEA is higher than that of GPI. The combination of both can increase the diagnostic efficiency and correct diagnosis rate of lung cancer patients. The paper discusses the status and clinical application value of GPI activity as a marker of lung cancer. It is considered that the measurement method of serum GPI activity is simple, reliable and inexpensive, and it is worthy of being popularized and applied in clinical practice in the future.